<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30225">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063217</url>
  </required_header>
  <id_info>
    <org_study_id>201304030</org_study_id>
    <secondary_id>P50AG005681-30</secondary_id>
    <nct_id>NCT02063217</nct_id>
  </id_info>
  <brief_title>Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction</brief_title>
  <official_title>Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to change the concentration of amyloid-beta in human
      cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Change in CSF amyloid beta concentration during sleep induction and sleep deprivation</measure>
    <time_frame>36 hours of CSF collection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Changing CSF Amyloid-beta Levels With Sleep Modification</condition>
  <arm_group>
    <arm_group_label>Sleep Induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 grams of sodium oxybate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleep Deprivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sleep deprivation for up to 36 hours with no naps or other sleep periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participant will sleep as normal under the same controlled conditions in a clinical research unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Oxybate</intervention_name>
    <arm_group_label>Sleep Induction</arm_group_label>
    <other_name>Xyrem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sleep deprivation</intervention_name>
    <description>36hr sleep deprivation</description>
    <arm_group_label>Sleep Deprivation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cognitively normal or CDR 0

          -  negative for amyloid deposition by PET Pittsburgh Compound-B (PIB) imaging or CSF
             amyloid-beta-42 concentration

               -  18

        Exclusion Criteria:

          -  diagnosis of a sleep disorder such as sleep apnea, narcolepsy, or restless leg
             syndrome

          -  positive ambulatory sleep study for obstructive sleep apnea (AHI &gt; 5 respiratory
             events per hour) that will be performed as part of initial screening prior to
             enrollment

          -  Clinical Dementia Rating (CDR) &gt; 0

          -  tremor or other neurologic injury in the non-dominant upper extremity (such as stroke
             or tremor) that would prevent the use of actigraphy

          -  current sleep walking or other sleep parasomnia

          -  diagnosis and treatment of stroke, myocardial infarction or heart attack,

          -  coronary artery disease, atrial fibrillation, or congestive heart failure

          -  diagnosis and treatment of asthma or Chronic Obstructive Pulmonary Disease (COPD)

          -  diagnosis and treatment of bipolar disorder, major depression, or Schizophrenia

          -  current urinary or fecal incontinence

          -  currently on a low salt diet

          -  diagnosis and treatment of a neurologic disorder such as Parkinson's disease,
             epilepsy, multiple sclerosis

          -  currently taking any blood thinner medications such as warfarin, Plavix, or Aspirin

          -  kidney disease resulting in renal impairment

          -  liver disease resulting in hepatic dysfunction

          -  Pregnancy

          -  currently taking sedating medications such as benzodiazepines
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Lucey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer McLeland, MSW, MA</last_name>
    <phone>314-747-3819</phone>
    <email>mclelandj@neuro.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Toedebusch, BS</last_name>
    <phone>314-747-0646</phone>
    <email>toedebuschc@neuro.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer McLeland, MSW, MA</last_name>
      <phone>314-747-3819</phone>
      <email>mclelandj@neuro.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cristina Toedebusch, BS</last_name>
      <phone>314-747-0646</phone>
      <email>toedebuschc@neuro.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brendan Lucey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
